Bicara is a well-funded, high-risk oncology bet whose upside hinges on whether ficerafusp alfa can convert promising early survival data into pivotal Phase 3 success.
Overview
Bicara Therapeutics is a pre-commercial oncology biotech focused on first-in-class bifunctional antibodies for solid tumors. Its lead asset, ficerafusp alfa, combines EGFR inhibition with localized TGF-β trapping and is in pivotal Phase 3 testing with pembrolizumab for first-line HPV-negative recurrent/metastatic HNSCC. The company has no product revenue, but strong early clinical efficacy, FDA Breakthrough Therapy Designation, global trial execution, and substantial unmet need create meaningful upside if pivotal data confirm durable survival benefits.